Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Feature|Articles|August 19, 2026
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
Author(s)Mohd Haque
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
Advertisement
Advertisement
Pharma companies have spent the last several years testing AI across discovery, development, manufacturing, and commercialization. With the potential to create $60 billion to $110 billion annual economic value across the industry, AI has become too important to remain stuck in pilot mode. Today, only a small group of companies is starting to turn AI into measurable business gains, with Boston Consulting Group finding that AI-first biopharma companies are reporting 5 percent to 15 percent revenue uplift.
Related to this article
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Pfizer and J&J supply chain experts on why health authorities now ask not just whether your quality systems work — but how fast you can adapt.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.
Shionogi is acquiring IntraBio for $2 billion, Gate Bioscience expands its collaboration with Eli Lilly, and Alector licenses Al050 to Genentech.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
Advertisement
Advertisement